ライフサイエンスコーパス: UC

1 UC and CD were genetically more similar to each other (r

2 UC in remission was define by steroid-free clinical remi

3 UC transferring through the processing center were more

4 UC-514321, a structural analog of NSC-370284, exhibited

5 UC-B3 within the infant.

6 UC-B3) was distinct at the strain level from its closest

7 UC-MSC-treated patients presented no adverse events rela

8 UC-MSCs in vitro, compared with bone marrow-derived mese

9 UCd is significantly associated with hypertension (odds

10 13 concentrations (CD: 1.8-fold, P = 0.0077; UC: 1.9-fold, P = 0.056) in the serum of untreated pedia

11 rroelectric transition temperature T(c) of 1-UC SnTe film is greatly enhanced from the bulk value of

12 placebo=75, quetiapine=125, risperidone=124, UC=30 and ziprasidone=32), 4 of which were conference ab

13 lence (86.5% to 96.6% INT vs. 90.1% to 98.2% UC; P = 0.808) in a modified intention-to-treat analysis

14 HCP (BHCP trained to provide SBIRT), and (3) UC.

15 e 312 CD patients (1.9%) and five of the 361 UC patients (1.4%) were diagnosed with CMV colitis.

16 Moreover, 2- to 4-UC SnTe films show robust ferroelectricity at room tempe

17 roups (75.1% to 81.2% INT vs. 73.6% to 79.5% UC; P = 0.369).

18 and/or IBD (CD: RR, 1.34; 95% CI, 1.11-1.61; UC: RR, 1.25; 95% CI, 1.03-1.53).

19 ncreased in both groups (+12.9 INT vs. +10.8 UC; P = 0.216), as did caries prevalence (86.5% to 96.6%

20 the metabolites in stool of 183 subjects (82 UC, 50 CD, and 51 healthy controls) were determined.

21 d 19,735 IBD cases (10,856 CD cases and 8879 UC cases) of known smoking status.

22 =18 years of age) with a diagnosis of active UC (total Mayo score of 6-12 points and moderately-to-se

23 bulatory patients with mild to severe active UC.

24 ve patients with moderate to severely active UC during the first 2 weeks of infliximab therapy at the

25 in patients with moderate to severely active UC who had not responded to standard therapy.

26 fewer withdrawals from therapy due to active UC.

27 lected from a subset of patients with active UC (n = 10) or CD (n = 8) to investigate associations be

28 d in colon tissues from patients with active UC or CAC than from patients with other disorders or con

29 Twenty-six patients with active UC were prospectively recruited and grouped according to

30 c biopsy specimens from patients with active UC, the miR214 inhibitor reduced inflammation by increas

31 sion in small series of patients with active UC.

32 mpare the survival of patients with advanced UC treated with elective colectomy or medical therapy.

33 atients aged 50 years or older with advanced UC.

34 domized to intravenous infusion of allogenic UC-MSCs (Cellistem, Cells for Cells S.A., Santiago, Chil

35 mong adherent INT children (+8.9) than among UC children (+10.8; P = 0.028) in a per-protocol analysi

36 NSC-370284 and UC-514321 both directly target STAT3/5, transcriptional

37 ated with increased susceptibility to CD and UC (OR: 2.12; 95% CI: 1.33, 3.36 and OR: 1.61; 95% CI: 1

38 a derived from microarray analysis of CD and UC biopsies and human interactome databases.

39 ta-analyses each for CD, UC, and IBD (CD and UC combined), comparing data for never vs ever smokers,

40 The viromes of CD and UC patients were disease and cohort specific.

41 s (inflamed and uninflamed tissues in CD and UC).

42 population; we also replicated IBD, CD, and UC loci identified in European populations.

43 es across 2 modalities of implementation and UC.

44 Patients in the pediatrician-only and UC arms had higher odds of being referred to specialty t

45 f biomarkers for risk assessments of SCC and UC.

46 ient cells was comparable between BE-SEC and UC samples.

47 5.4%, and 2.0% for in-person, telephone, and UC groups, respectively (P = .004, P = .009, and P = .46

48 unwashed eggs stored at 7 degrees C (WC and UC for washed and unwashed eggs, respectively) and 25 de

49 I3, PTEN, and TJP1 in colonic IBD as well as UC mucosa, and between inflammation and increased expres

50 colonization in symptomatic and asymptomatic UC.

51 patients with symptomatic than asymptomatic UC (22.2 vs 6.9; P = .021).

52 as associated with an increased risk of both UC and CD (OR: 2.91; 95% CI: 1.49, 5.68 and OR: 3.00; 95

53 Together, hypoimmunogenicity of both UC-MSCs and ADSCs supports their suitability for allogen

54 of adverse events (47.1%), mostly caused by UC, than patients receiving methotrexate (26.7%; P = .03

55 ine the relationship between urinary cadmium(UCd) and hypertension and impaired kidney function at lo

56 family are frequent in urothelial carcinoma (UC) and may represent viable therapeutic targets.

57 CC) and 3-fold risk of urothelial carcinoma (UC) compared with the general population.

58 renal insufficiency on urothelial carcinoma (UC) prognosis has been investigated by numerous studies.

59 progressive metastatic urothelial carcinoma (UC).

60 C, OR = 4.90) than in urothelial carcinomas (UC, OR = 3.62).

61 elephone counseling (n = 34), or usual care (UC) (n = 33).

62 15, 2012, and June 25, 2015, to usual care (UC) (n = 75) or UC plus a palliative care intervention (

63 andomised, placebo-controlled or usual care (UC) controlled trials of antipsychotics in adult patient

64 eptember 28, 2011, randomized to usual care (UC) or the TOP intervention, and followed up for 12 mont

65 sis (n = 204), to compare PTC to usual care (UC).

66 omly allocated to 1 of 4 groups: Usual Care (UC); Food, Activity, and Breastfeeding (FAB); Sleep; or

67 ength single-level intervention (usual care [UC]) on treatment effectiveness and incremental cost-eff

68 ead Start classrooms (26 INT, 26 usual care [UC]).

69 We performed 3 meta-analyses each for CD, UC, and IBD (CD and UC combined), comparing data for nev

70 disproportionate occurrence of known RA, CD, UC, or T1D risk alleles in AD.

71 CD/UC 84/28, male/female 50/62, mean age CD/UC: 36/35 years) were enrolled in this consecutive cohor

72 IBD patients (with 214 TDM measurements, CD/UC 84/28, male/female 50/62, mean age CD/UC: 36/35 years

73 Unsupervised models revealed overlap of CD/UC with broad clustering but no clear subtype delineatio

74 tin telluride (SnTe), down to a 1-unit cell (UC) limit.

75 bilical cord-derived mesenchymal stem cells (UC-MSC) are easily accessible and expanded in vitro, pos

76 14, more than 46 000 unaccompanied children (UC) from Central America crossed the US-Mexico border.

77 by the humanized anti-ROR1 mAb cirmtuzumab (UC-961).

78 ion (rG) between PSC and ulcerative colitis (UC) (rG = 0.29) was significantly greater than that betw

79 ory bowel diseases (IBD) ulcerative colitis (UC) and Crohn's disease (CD) cause significant morbidity

80 ory bowel diseases (IBD) ulcerative colitis (UC) and Crohn's disease (CD) cause significant morbidity

81 n origin, which includes ulcerative colitis (UC) and Crohn's disease (CD).

82 ith PSC with and without ulcerative colitis (UC) and explanted PSC livers.

83 ophage phenotypes in CD, ulcerative colitis (UC) and healthy controls (HC), and in CD, to compare mac

84 ng Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBDU) i

85 Crohn's disease (CD) and ulcerative colitis (UC) and to compare the occurrence of certain diseases co

86 Ulcerative colitis (UC) belongs to inflammatory bowel disorders, a group of

87 re endoscopic healing in ulcerative colitis (UC) clinical trials.

88 he medical management of ulcerative colitis (UC) has improved through the development of new therapie

89 Crohn's disease (CD) and ulcerative colitis (UC) in a case-only study of patients and in mouse models

90 pment and progression of ulcerative colitis (UC) in human patients.

91 Ulcerative colitis (UC) is a chronic, relapsing and debilitating idiopathic

92 The odds of having ulcerative colitis (UC) or Crohn disease (CD) were elevated in carriers of t

93 Crohn's disease (CD) or ulcerative colitis (UC) patients initiating anti-integrin therapy (vedolizum

94 common in patients with ulcerative colitis (UC) than expected.

95 ication in patients with ulcerative colitis (UC) undergoing proctocolectomy with ileal pouch-anal ana

96 Crohn's disease (CD), or ulcerative colitis (UC) were investigated.

97 ble bowel disease (IBD), ulcerative colitis (UC), and Crohn's disease (CD).

98 hway has been related to ulcerative colitis (UC), and soluble ST2 (sST2), to disease severity.

99 Crohn's disease (CD) and ulcerative colitis (UC), are complex chronic inflammatory conditions of the

100 Human ulcerative colitis (UC), UC-associated CRC, and sporadic CRC specimens have

101 mal invasive approach in ulcerative colitis (UC), using the comprehensive complication index (CCI).

102 e in the pathogenesis of ulcerative colitis (UC)-few data are available from treatment-naive patients

103 ibute to pathogenesis of ulcerative colitis (UC).

104 tokines in patients with ulcerative colitis (UC).

105 erate to severely active ulcerative colitis (UC).

106 in 5 genes of paediatric ulcerative colitis (UC).

107 ia coli in the course of ulcerative colitis (UC).

108 aluated in patients with ulcerative colitis (UC).

109 isease (CD) and 361 with ulcerative colitis (UC).

110 has been associated with ulcerative colitis (UC).

111 lure after colectomy for ulcerative colitis (UC).

112 sease (CD), p = 0.03 for Ulcerative Colitis (UC); Odds Ratio 1.09, 95 % Confidence Interval: 1.02-1.1

113 Crohn's disease (CD) and ulcerative colitis (UC); these subtypes share overlapping genetic and clinic

114 hn's disease (n = 61) or ulcerative colitis (UC, n = 74) or from patients without inflammatory bowel

115 IBD; Crohn disease [CD], ulcerative colitis [UC]) and is inversely related to type 1 diabetes (T1D) a

116 's disease [CD], 23 with ulcerative colitis [UC]), and 30 children without IBD (controls).

117 ients with IBD (211 with ulcerative colitis [UC], 234 with Crohn's disease [CD]; 236 male), enrolled

118 cutive subjects (31 with ulcerative colitis [UC], 57 with Crohn's disease [CD], and 22 healthy indivi

119 th neurogenic potential from umbilical cord (UC-MSCs) and paediatric adipose tissue (ADSCs), while hi

120 iven on the Unified transient testing cycle (UC) using four different fuels.

121 n 111 patients with corticosteroid-dependent UC at 26 medical centers in Europe from 2007 through 201

122 ents with corticosteroid-resistant/dependent UC, anti-TNF or vedolizumab therapy is recommended.

123 efficacy in patients with steroid-dependent UC.

124 Here we designed UC-rich and CU-rich 10-nt sequences for engagement of bo

125 commitment and real-time economic dispatch (UC-ED) model simulates hourly system operations.

126 ta in the distal gut of pigs fed E. faecalis UC-100 substituting antibiotics, this study assessed fec

127 onstrated that dietary Enterococcus Faecalis UC-100 substituting antibiotics enhanced growth and heal

128 Fifty-five UC patients met the criteria for being in remission.

129 <18 years) were identified via ICD codes for UC and CD in Swedish registers between 1993 and 2010 (n

130 astomosis is recommended after colectomy for UC, IRA is still performed.

131 Ta-IPAA for UC is a safe procedure, resulting in fewer patients with

132 study, which included patients with IRA for UC performed between 1960 and 2014.

133 associations of genome-wide significance for UC.

134 NOD2) for CD; and KCNQ2 (near TNFRSF6B) for UC.

135 cond of the two White Papers from the fourth UC Davis Cardiovascular Symposium Systems Approach to Un

136 This paper is the outcome of the fourth UC Davis Systems Approach to Understanding Cardiac Excit

137 ctomy, revealing locally advanced high-grade UC invading the renal parenchyma (pT3).

138 Biopsy confirmed metastatic high-grade UC.

139 Among 15 hospitalized UC, 4 (44%) of 9 tested positive for influenza viruses,

140 ical charts were abstracted for hospitalized UC.

141 neumococcal blood isolates from hospitalized UC and nasopharyngeal isolates were characterized by ser

142 urified by ultracentrifugation (UC), however UC has limitations, including resulting in, operator-dep

143 rvations reported on NHE expression in human UC, the present study was initiated to identify whether

144 In UC patients in remission the FC level in the lower span

145 In UC patients, serum 25(OH)D concentration is inversely co

146 In UC patients, sST2 is further increased by corticosteroid

147 In UC-B3, the population genetic underpinnings of phase var

148 nhibitor of the ErbB family) has activity in UC and if specific ERBB molecular alterations are associ

149 f pathophysiologic occurrence of diarrhea in UC and suggests that targeting CFTR and CFTR-containing

150 Depression improved in UC + PAL patients (HADS-depression difference = -1.94 po

151 Spiritual well-being was improved in UC + PAL versus UC-alone patients (FACIT-Sp difference =

152 t how E. coli contributes to inflammation in UC is still unknown.

153 n the IL1RL1 distal promoter are involved in UC and affect glucocorticoid-mediated ST2 expression.

154 ion in both astrocytes and hNSCs, but not in UC-MSCs and ADSCs, either undifferentiated or differenti

155 es from CD patients (25/35, 71 %), rarely in UC (1/9, 11 %) and not at all in healthy controls (0/18)

156 a is considered to play an important role in UC pathogenesis, but how E. coli contributes to inflamma

157 were examined by ELISA and PCR sequencing in UC patients receiving corticosteroids.

158 116(A) are associated with increased sST2 in UC patients on corticosteroids.

159 tal period when (n-6) consumption may induce UC is not known.

160 This study affirms that inpatient UC patients undergoing colonic resection are at high ris

161 ) or UC plus a palliative care intervention (UC + PAL) (n = 75) at a single center.

162 In June-July, UC aged 9-17 years in 4 shelters and 1 processing center

163 ired kidney function at low exposure levels (UCd: GM 1.3 mug/g creatinine).

164 ether rectosigmoidoscopy adequately measures UC activity in the more proximal colon.

165 vival in patients with refractory metastatic UC.

166 t 24 weeks (EX, 26.9+/-7.7 mL/kg per minute; UC, 23.4+/-6.0 mL/kg per minute; P<0.001).

167 onsumption (EX, 26.7+/-7.0 mL/kg per minute; UC, 23.9+/-6.6 mL/kg per minute; P=0.002) at 8 weeks, wh

168 using a unit commitment and dispatch model (UC&D).

169 Nonhospitalized UC with influenza-like illness were interviewed, and nas

170 Among 774 nonhospitalized UC, 185 (24%) yielded pneumococcus, and 70 (38%) were se

171 te-Guerin-refractory, high-grade noninvasive UC.

172 o follow changes in inflammatory activity of UC patients who respond or not to treatment identifies s

173 high degree of correlation in assessments of UC activity made by rectosigmoidoscopy vs colonoscopy.

174 the chemical composition and bioactivity of UC.

175 x, air cell size, and S-ovalbumin content of UC were significantly the most superior, followed by tho

176 2 immune response during the early course of UC.

177 of cytokines, allowing the identification of UC and CC patients, with area under the curve (AUC) = 0.

178 and efficacy of the intravenous infusion of UC-MSC in patients with chronic stable heart failure and

179 Intravenous infusion of UC-MSC was safe in this group of patients with stable he

180 trial has evaluated intravenous infusion of UC-MSCs in these patients.

181 arch identified studies on the management of UC.

182 biomarker in predicting clinical outcome of UC patients.

183 nic mucosa of patients in the acute phase of UC.

184 for renal insufficiency on the prognosis of UC needs to be further studied.

185 40 degree results in an improved quality of UC.

186 n and/or prolongation of remission stages of UC.

187 n and/or prolongation of remission stages of UC.

188 similar when stratified according to type of UC surgery.

189 e prognostic value of renal insufficiency on UC, we performed a systematic review and meta-analysis b

190 une 25, 2015, to usual care (UC) (n = 75) or UC plus a palliative care intervention (UC + PAL) (n = 7

191 llowed us to distinguish children with CD or UC from controls; profiles correlated with disease outco

192 no consensus for posttransplantation RCC or UC screening as supporting data are limited.

193 oup, antipsychotics were superior to placebo/UC in terms of response rate (RR=0.22, NNT=2), delirium

194 ation (RR=4.59, NNH=5) compared with placebo/UC.

195 In addition, at all follow-up time points, UC-MSC-treated patients displayed improvements of New Yo

196 ctivity in patients with platinum-refractory UC with HER2 or ERBB3 alterations.

197 ecimens from patients with active, resolving UC and healthy individuals without UC (controls).

198 urther investigation in molecularly selected UC.

199 uidelines addressed the management of severe UC in the hospitalized patient.

200 icacy of these drugs in patients with severe UC.

201 la ventral nerve cord of a slit allele (slit-UC) that cannot be cleaved revealed that midline repulsi

202 Dscam1 and robo1 strongly resemble the slit-UC phenotype, suggesting they cooperate in longitudinal

203 t colon, a model that has been used to study UC.

204 y Index score of 150 or more and symptomatic UC by a partial Mayo score of 2 or more.

205 with CD (vs control; P = 1.1 x 10(-10)) than UC (vs control; P = 2.8 x 10(-3)).

206 eater reach than UC, more effectiveness than UC, and is well within the range of acceptability for co

207 saster is associated with greater reach than UC, more effectiveness than UC, and is well within the r

208 It is clear that UC active site recovery does not revert fully back to a

209 Our results indicate that UC patients with pre-operative renal insufficiency tend

210 The UC Davis Cardiovascular Symposium is a biannual event th

211 A-1 RRM23 construct preferentially binds the UC-rich RNA ligand (5-UUUUUACUCC-3).

212 .5% for the INT group and 22.8/90.1% for the UC group, respectively.

213 rom 35.0 to 29.1) compared with those in the UC arm (from 33.5 to 32.1) at 6 months (beta = -3.81; P

214 In the UC cohort, adverse postoperative outcome rates between t

215 n </= 200 mug/g) (rs 0.38; p = 0.004) in the UC in remission group.

216 motherapy dose adjustments than those in the UC or Onco-Move groups (P = .002).

217 Only the UC-MSC-treated group exhibited significant improvements

218 and 90 days presented alloantibodies to the UC-MSCs (n=7).

219 ved more rapidly in the INT group versus the UC group (P = 0.006).

220 1% decrease among women randomly assigned to UC (P = .05).

221 that vitamin D deficiency may contribute to UC inflammation by disrupting epithelial barrier functio

222 Randomization to UC + PAL did not affect rehospitalization or mortality.

223 herapy compared with 16 of 132 randomized to UC (12.1%) (odds ratio, 18.08 [95% CI, 7.96-41.06]; P <

224 Patients randomized to UC + PAL versus UC alone had clinically significant incr

225 iated with greater reach and was superior to UC in reducing the prevalence of PTSD in the full popula

226 1 SNPs rs6543115(C) confer susceptibility to UC and is contained in the GRE, which may modulate gluco

227 years, when he developed a left upper-tract UC.

228 fluence on both the light harvesting and TTA-UC efficiency.

229 ersion via triplet-triplet annihilation (TTA-UC) and increase maximum theoretical solar cell efficien

230 th the lowest value yet reported for any TTA-UC system.

231 highest photocurrent yet generated from TTA-UC (0.158 mA cm(-2)) under 1 sun.

232 III)(pz-py-pz)2 devices achieved maximum TTA-UC efficiency at excitation intensities well below solar

233 iplet-triplet annihilation upconversion (TTA-UC) is presented.

234 riplet annihilation photon upconversion (TTA-UC).

235 ty of Hsc70 in the presence of the 3' poly U/UC motif of HCV RNA.

236 n complex by primarily binding to the poly U/UC motifs in HCV RNA.

237 on length of the U-core motif of the poly-U/UC PAMP and are recognized by RIG-I to induce innate imm

238 Human ulcerative colitis (UC), UC-associated CRC, and sporadic CRC specimens have simil

239 onally been purified by ultracentrifugation (UC), however UC has limitations, including resulting in,

240 adder cancer, as well as in T24, J82, and UM-UC-3 but not in 5637, RT112, and RT4 cell lines.

241 tment of mice bearing contralateral flank UM-UC-3 and RT112 xenografts selectively arrested tumor gro

242 ASS1 overexpression in UM-UC-3 or ASS1 silencing in RT112 cells reversed these eff

243 afts selectively arrested tumor growth in UM-UC-3 xenografts, which had reduced tumor size, reduced K

244 ZTAC (ZTACSEC), relative to an uncorrected (UC) ZTAC (ZTACUC) and a CT atlas-based attenuation corre

245 Under UC, all patients were referred only to Skills for Psycho

246 difference = -1.94 points; p = 0.020) versus UC-alone patients, with similar findings for anxiety (HA

247 ICD shocks were infrequent (EX=4 versus UC=8), with no differences in hospitalizations or deaths

248 Patients randomized to UC + PAL versus UC alone had clinically significant incremental improvem

249 l well-being was improved in UC + PAL versus UC-alone patients (FACIT-Sp difference = 3.98 points; p

250 me variants in opposite directions for CD vs UC.

251 aling (15.4% of patients with CD, 17.4% with UC).

252 n Americans with IBD (1646 with CD, 583 with UC, and 116 inflammatory bowel disease unclassified) and

253 with IBD and identified loci associated with UC in only this population; we also replicated IBD, CD,

254 ry n-6 fatty acids have been associated with UC in prospective studies.

255 sion, and spiritual well-being compared with UC alone.

256 The reach of SC compared with UC for 2 years, the 2-year reduction in prevalence of PT

257 ental cost-effectiveness of SC compared with UC was $3428.71 to $6857.68 per disability-adjusted life

258 similar expression signatures compared with UC-purified samples.

259 ooth surfaces (dmfs) increment compared with UC.

260 Three of the 4 patients with UC </=1 year entered remission, compared with 6 of 34 of

261 Sixty-eight patients with UC and 33 patients with hereditary familiar colon cancer

262 vels of GATA3 are increased in patients with UC and correlate with production of inflammatory cytokin

263 lates with disease activity in patients with UC and progression to colorectal cancer.

264 IL23) in mucosal samples from patients with UC compared with patients with colon-only CD.

265 d in treatment-naive pediatric patients with UC compared with patients with Crohn's disease (CD)-asso

266 integrin alphaE(+) cells from patients with UC expressed higher levels of granzyme A messenger RNA (

267 and IL17A mRNAs distinguished patients with UC from patients with colon-only CD (P = .001; area unde

268 We were able to distinguish patients with UC from those with colon-only CD based on increased muco

269 Colonic biopsies from patients with UC had reduced levels of inflammation-resolving DHA-deri

270 DISCUSSION: Patients with UC have a high risk of IRA failure, particularly when co

271 efficacy and safety of FMT for patients with UC in a double-blind randomized trial.

272 alence of IBS-like symptoms in patients with UC in remission and longstanding disease in comparison t

273 The patients with UC in remission tended to have lower scores on total GSR

274 trolizumab, as well as from 21 patients with UC or without inflammatory bowel disease (controls) enro

275 re lower in colon tissues from patients with UC than healthy and resolving mucosa.

276 rgent (P = .31) surgeries when patients with UC were compared with patients with CD.

277 in colon tissues can identify patients with UC who are most likely to benefit from etrolizumab; expr

278 sis of data collected from 110 patients with UC who participated in a phase 2 placebo-controlled tria

279 Patients with UC with longstanding disease and in remission do not hav

280 The prevalence of IBS in patients with UC with longstanding disease is not known.

281 As in colonic biopsies from 60 patients with UC, 50 with CD, and 30 controls.

282 e higher in colon tissues from patients with UC, but not ileal Crohn's disease, than control tissues;

283 n pattern in rectal tissues of patients with UC, characterized by detection of IL13 mRNA, that predic

284 As in 401 colon specimens from patients with UC, Crohn's disease, irritable bowel syndrome, sporadic

285 6 studies which involved 5,232 patients with UC, investigated the relationship between pre-operative

286 In patients with UC, postoperative mortality was significantly lower amon

287 me approach was introduced for patients with UC, resulting in decreased invasiveness.

288 t the sites of inflammation in patients with UC, which can lead to immune system activation, whilst,

289 apy and remission in pediatric patients with UC.

290 ndoscopic sub-score of 0-1 for patients with UC.

291 n of steroid-free remission in patients with UC.

292 e changes were not observed in patients with UC.

293 be developed for treatment of patients with UC.

294 = .009, and P = .46 comparing in-person with UC, telephone with UC, and in-person with telephone, res

295 comparing in-person with UC, telephone with UC, and in-person with telephone, respectively).

296 mission, compared with 6 of 34 of those with UC >1 year (P = .04, Fisher's exact test).

297 life were observed in patients treated with UC-MSCs.

298 Notably, treatment with UC-961 inhibited engraftment of ROR1+ leukemia cells in

299 ing of either ROR1 or ROR2 or treatment with UC-961 inhibited these effects.

300 resolving UC and healthy individuals without UC (controls).

301 While the majority report worse UC outcomes in patients with renal insufficiency, the re